

# Larry W Moreland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9327888/publications.pdf>

Version: 2024-02-01

241  
papers

39,463  
citations

9264

74  
h-index

2629

194  
g-index

253  
all docs

253  
docs citations

253  
times ranked

30132  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	1.9	2
2	Analysis of Complement Gene Expression, Clinical Associations, and Biodistribution of Complement Proteins in the Synovium of Early Rheumatoid Arthritis Patients Reveals Unique Pathophysiologic Features. <i>Journal of Immunology</i> , 2022, 208, 2482-2496.	0.8	9
3	A review of biosimilars for rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102234.	3.5	4
4	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	1.4	2
5	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. <i>Journal of Rheumatology</i> , 2021, 48, 1472-1479.	2.0	8
6	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	5.6	34
7	Post-GWAS functional studies reveal an RA-associated <i>CD40</i> -induced NF- $\kappa$ B signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors. <i>Human Molecular Genetics</i> , 2021, 30, 823-835.	2.9	4
8	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	2.1	21
9	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021, 16, e0244187.	2.5	16
10	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.8	3
11	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	1.9	33
12	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	2.0	20
13	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
14	Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 488-497.	2.5	2
15	Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2020, 73, 1372-1378.	3.4	11
16	Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers. <i>Journal of Diagnostic Medical Sonography</i> , 2020, 36, 300-310.	0.3	0
17	B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF- $\alpha$ production. <i>Clinical Immunology</i> , 2020, 212, 108360.	3.2	12
18	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25

#	ARTICLE	IF	CITATIONS
19	Transcriptional Regulation of CD40 Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated CD40 Locus. <i>Genes</i> , 2020, 11, 1526.	2.4	4
20	Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. <i>Arthritis Care and Research</i> , 2019, 71, 521-529.	3.4	24
21	Contraception Use Among Reproductive-Age Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2019, 71, 1132-1140.	3.4	22
22	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	3.4	43
23	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Week, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	5.6	64
24	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37
25	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019, 20, 928-942.	14.5	760
26	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
27	Inflammatory joint diseases and atherosclerosis: time to look beyond the "lipid paradox". <i>Current Opinion in Lipidology</i> , 2019, 30, 342-349.	2.7	4
28	Pain and Catastrophizing in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 232-236.	0.9	8
29	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3—3 Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019, 71, 319-322.	3.4	3
30	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	1.9	28
31	Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2018, 70, 197-204.	3.4	65
32	Family Planning Counseling for Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2018, 70, 169-174.	3.4	28
33	14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T C 2 and CD8 + lymphocytes from patients with scleroderma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 109-119.e6.	2.9	22
34	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	2.5	6
35	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018, 20, 139.	3.5	93
36	Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 475-487.	1.9	32

#	ARTICLE	IF	CITATIONS
37	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	5.6	131
38	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	5.6	271
39	Persistence of Disease-associated Anti-Citrullinated Protein Antibody-expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission. Arthritis and Rheumatology, 2017, 69, 1176-1186.	5.6	34
40	Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study. American Journal of Epidemiology, 2017, 186, 245-254.	3.4	5
41	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	5.6	130
42	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
43	Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis and Rheumatology, 2017, 69, 46-57.	5.6	48
44	Cardiovascular Disease Risk in Patients with Rheumatic Diseases. Clinics in Geriatric Medicine, 2017, 33, 105-117.	2.6	17
45	Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project. Journal of Rheumatology, 2017, 44, 11-17.	2.0	19
46	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. Journal of Medical Internet Research, 2017, 19, e50.	4.3	24
47	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 98-101.	0.8	3
48	Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Research and Therapy, 2016, 18, 108.	3.5	48
49	Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis and Rheumatology, 2016, 68, 577-586.	5.6	43
50	Analysis of CXCR5+Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. Scientific Reports, 2016, 6, 39474.	3.3	17
51	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460.	12.8	73
52	Cost-effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 1751-1757.	3.4	27
53	Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status. BMC Musculoskeletal Disorders, 2016, 17, 10.	1.9	13
54	Reply. Arthritis and Rheumatology, 2016, 68, 555-556.	5.6	1

#	ARTICLE	IF	CITATIONS
55	Increased pretreatment serum IFN- $\gamma$ /IL-6 ratio predicts non-response to tumour necrosis factor $\alpha$ inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.9	59
56	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
57	Comprehensive Appraisal of Magnetic Resonance Imaging Findings in Sustained Rheumatoid Arthritis Remission: A Substudy. <i>Arthritis Care and Research</i> , 2015, 67, 929-939.	3.4	30
58	Rheumatoid Arthritis, Anti-CCP Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2311-2322.	5.6	69
59	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	2.0	87
60	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
61	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e87645.	2.5	34
62	Socioeconomic Disparities in the Health of African Americans With Rheumatoid Arthritis From the Southeastern United States. <i>Arthritis Care and Research</i> , 2014, 66, 1808-1817.	3.4	13
63	Complementary and Alternative Medicine Use in African Americans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 180-189.	3.4	26
64	Determinants of Mortality Among Postmenopausal Women in the Women's Health Initiative Who Report Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 497-507.	5.6	30
65	Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 417.	4.7	13
66	Rheumatoid Arthritis in the Women's Health Initiative: Methods and Baseline Evaluation. <i>American Journal of Epidemiology</i> , 2014, 179, 917-926.	3.4	11
67	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
68	Sedentary Behavior and Mortality in Older Women. <i>American Journal of Preventive Medicine</i> , 2014, 46, 122-135.	3.0	94
69	Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 785-786.	0.9	5
70	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 539-540.	6.7	0
71	Validation of the Methotrexate-First Strategy in Patients With Early, Poor Prognosis Rheumatoid Arthritis: Results From a Two-Year Randomized, Double-Blind Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1985-1994.	6.7	62
72	Comparison of the Disease Activity Score Using Erythrocyte Sedimentation Rate and C-reactive Protein in African Americans with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1812-1822.	2.0	34

#	ARTICLE	IF	CITATIONS
73	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. <i>Journal of Rheumatology</i> , 2013, 40, 787-797.	2.0	112
74	Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1430-1438.	6.7	124
75	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	3.5	146
76	Phenome-Wide Association Study (PheWAS) for Detection of Pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network. <i>PLoS Genetics</i> , 2013, 9, e1003087.	3.5	171
77	Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial. <i>Journal of Rheumatology</i> , 2013, 40, 572-578.	2.0	19
78	Predictive Value of Autoantibody Testing for Validating Self-reported Diagnoses of Rheumatoid Arthritis in the Women's Health Initiative. <i>American Journal of Epidemiology</i> , 2013, 177, 887-893.	3.4	7
79	Associations of Alcohol Use with Radiographic Disease Progression in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1498-1504.	2.0	7
80	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	21.4	24
81	Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1804-1810.	3.4	17
82	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2824-2835.	6.7	325
83	Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women's Health Initiative Calcium plus Vitamin D trial. <i>Rheumatology International</i> , 2012, 32, 3823-3830.	3.0	30
84	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	3.4	1,413
85	Impact of interactions of cigarette smoking with <i>NAT2</i> polymorphisms on rheumatoid arthritis risk in African Americans. <i>Arthritis and Rheumatism</i> , 2012, 64, 655-664.	6.7	26
86	Inhibition of Spleen Tyrosine Kinase for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 377-378.	4.7	0
87	JAK Inhibition in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 379-380.	4.7	2
88	Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 381-382.	4.7	0
89	Radiographic severity of Rheumatoid Arthritis in African Americans: Results from a multicenter observational study. <i>Arthritis Care and Research</i> , 2010, 62, 624-631.	3.4	33
90	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95

#	ARTICLE	IF	CITATIONS
91	Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2219-2226.	6.7	28
92	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
93	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
94	A functional <i>RANKL</i> polymorphism associated with younger age at onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2864-2875.	6.7	35
95	Associations of cigarette smoking with rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010, 62, 3560-3568.	6.7	44
96	Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010, 62, 3547-3553.	6.7	56
97	Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy. <i>Drug Design, Development and Therapy</i> , 2010, Volume 4, 263-278.	4.3	70
98	Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 625-626.	0.9	22
99	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 855-866.	3.0	19
100	Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R75.	3.5	20
101	Vitamin D Status and Its Associations with Disease Activity and Severity in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 275-281.	2.0	97
102	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
103	The Safety of Flavocoxid, a Medical Food, in the Dietary Management of Knee Osteoarthritis. <i>Journal of Medicinal Food</i> , 2009, 12, 1143-1148.	1.5	36
104	An African Ancestry-Specific Allele of CTLA4 Confers Protection against Rheumatoid Arthritis in African Americans. <i>PLoS Genetics</i> , 2009, 5, e1000424.	3.5	11
105	Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor $\alpha$ Inhibitors. <i>Clinical Infectious Diseases</i> , 2009, 49, 924-927.	5.8	75
106	Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 132-143.	3.4	59
107	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 1102-1111.	6.7	137
108	Golimumab, a human anti-tumor necrosis factor $\alpha$ monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2272-2283.	6.7	387



#	ARTICLE	IF	CITATIONS
109	Anti-“cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis and Rheumatism, 2009, 60, 2211-2215.	6.7	26
110	Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis. Current Rheumatology Reports, 2009, 11, 309-310.	4.7	0
111	Certolizumab pegol in active rheumatoid arthritis. Current Rheumatology Reports, 2009, 11, 311-312.	4.7	1
112	Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis. Current Rheumatology Reports, 2009, 11, 313-314.	4.7	1
113	REL, encoding a member of the NF- $\kappa$ B family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nature Genetics, 2009, 41, 820-823.	21.4	305
114	Cytokines as Targets for Anti-inflammatory Agents. Annals of the New York Academy of Sciences, 2009, 1182, 88-96.	3.8	8
115	Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study. Journal of Rheumatology, 2009, 36, 736-742.	2.0	114
116	The HLA-“DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis and Rheumatism, 2008, 58, 349-358.	6.7	77
117	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis and Rheumatism, 2008, 58, 953-963.	6.7	159
118	A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis and Rheumatism, 2008, 58, 1810-1822.	6.7	99
119	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 59, 762-784.	6.7	1,311
120	Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-“conjugated uricase) in patients with treatment-“failure gout: Results of a phase II randomized study. Arthritis and Rheumatism, 2008, 58, 2882-2891.	6.7	156
121	Psoriatic arthritis: Current concepts on pathogenesis-oriented therapeutic options. Arthritis and Rheumatism, 2007, 56, 1051-1066.	6.7	53
122	Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clinical Immunology, 2007, 123, 235-243.	3.2	13
123	Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients. Drugs and Aging, 2006, 23, 167-178.	2.7	36
124	Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. New England Journal of Medicine, 2006, 354, 795-808.	27.0	1,127
125	Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. Annals of Internal Medicine, 2006, 144, 865.	3.9	643
126	Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiology and Drug Safety, 2006, 15, 11-18.	1.9	9



#	ARTICLE	IF	CITATIONS
127	Abatacept. Nature Reviews Drug Discovery, 2006, 5, 185-186.	46.4	158
128	Efficacy of costimulation blockade with abatacept in rheumatoid arthritis patients refractory to tumor necrosis factor- $\alpha$ inhibition. Current Rheumatology Reports, 2006, 8, 367-367.	4.7	0
129	Efficacy and safety of rituximab in rheumatoid arthritis patients refractory to methotrexate. Current Rheumatology Reports, 2006, 8, 368-368.	4.7	0
130	Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis and Rheumatism, 2006, 55, 287-293.	6.7	50
131	Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 3057-3059.	6.7	31
132	Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. Journal of Rheumatology, 2006, 33, 854-61.	2.0	78
133	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 2162-6.	2.0	71
134	Validation of American College of Rheumatology Classification Criteria for Knee Osteoarthritis Using Arthroscopically Defined Cartilage Damage Scores. Seminars in Arthritis and Rheumatism, 2005, 35, 197-201.	3.4	97
135	Effects of doxycycline on progression of osteoarthritis: Results of a randomized, placebo-controlled, double-blind trial. Arthritis and Rheumatism, 2005, 52, 2015-2025.	6.7	249
136	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism, 2005, 52, 2263-2271.	6.7	456
137	Humanized anti-interleukin-6 receptor antibody. Current Rheumatology Reports, 2005, 7, 381-381.	4.7	0
138	Febuxostat " Treatment for Hyperuricemia and Gout?. New England Journal of Medicine, 2005, 353, 2505-2507.	27.0	16
139	Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2005, 5, 1245-1254.	3.1	39
140	B cell targeted therapy: a new approach to the treatment of rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7, S1.	3.5	1
141	Unmet needs in rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7, S2.	3.5	26
142	Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. Journal of the National Medical Association, 2005, 97, 1155-60.	0.8	40
143	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. Journal of Rheumatology, 2005, 32, 832-40.	2.0	107
144	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1232-42.	2.0	89

#	ARTICLE	IF	CITATIONS
145	Rheumatoid arthritis: developing pharmacological therapies. Expert Opinion on Investigational Drugs, 2004, 13, 1007-1018.	4.1	27
146	How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?. Osteoarthritis and Cartilage, 2004, 12, 61-62.	1.3	3
147	High-dose versus low-dose ?-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Seminars in Arthritis and Rheumatism, 2004, 33, 249-263.	3.4	49
148	Ultrasound detection of bone erosions in rheumatoid arthritis: a comparison to routine radiographs of the hands and feet. Skeletal Radiology, 2004, 33, 80-84.	2.0	75
149	Adalimumab in rheumatoid arthritis. Current Rheumatology Reports, 2004, 6, 333-334.	4.7	4
150	Infliximab in rheumatoid arthritis. Current Rheumatology Reports, 2004, 6, 334-335.	4.7	3
151	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis and Rheumatism, 2004, 50, 1412-1419.	6.7	478
152	The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis and Rheumatism, 2004, 50, 2750-2756.	6.7	163
153	Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. Arthritis and Rheumatism, 2004, 51, 933-940.	6.7	21
154	Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis. Pharmacoeconomics, 2004, 22, 39-53.	3.3	60
155	Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 2858-2868.	6.7	133
156	Biologic Therapies on the Horizon for Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2004, 10, S32-S39.	0.9	15
157	Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. Journal of Rheumatology, 2004, 31, 1532-7.	2.0	49
158	Etanercept and methotrexate combination in rheumatoid arthritis. Current Rheumatology Reports, 2004, 6, 333.	4.7	1
159	Adalimumab in rheumatoid arthritis. Current Rheumatology Reports, 2004, 6, 333-4.	4.7	5
160	Adalimumab, a fully human anti-tumor necrosis factor $\alpha$ monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis and Rheumatism, 2003, 48, 35-45.	6.7	1,612
161	Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis and Rheumatism, 2003, 49, 819-825.	6.7	35
162	Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis. Drug Safety, 2003, 26, 23-32.	3.2	40

#	ARTICLE	IF	CITATIONS
163	Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig. <i>New England Journal of Medicine</i> , 2003, 349, 1907-1915.	27.0	973
164	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. <i>Clinical Therapeutics</i> , 2003, 25, 1700-1721.	2.5	279
165	Upcoming biologic agents for the treatment of rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2003, 15, 226-263.	4.3	50
166	Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. <i>Journal of Rheumatology</i> , 2003, 30, 691-6.	2.0	66
167	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 927-935.	4.1	7
168	Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 614-624.	6.7	570
169	Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002, 46, 1470-1479.	6.7	354
170	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1460-1469.	6.7	219
171	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002, 46, 1443-1450.	6.7	664
172	High-resolution ultrasound for the study of target joints in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1969-1970.	6.7	30
173	Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2002, 46, 2020-2028.	6.7	106
174	Glucocorticoids and rheumatoid arthritis: Back to the future?. <i>Arthritis and Rheumatism</i> , 2002, 46, 2553-2563.	6.7	88
175	Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 2983-2989.	6.7	194
176	Predicting outcomes in early rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2002, 4, 193-194.	4.7	2
177	Genetic Influences on Rheumatoid Arthritis in African Americans. <i>Immunologic Research</i> , 2002, 26, 015-026.	2.9	1
178	Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. <i>Arthritis Research</i> , 2001, 3, 247.	2.0	45
179	Early rheumatoid arthritis: a medical emergency?. <i>American Journal of Medicine</i> , 2001, 111, 498-500.	1.5	26
180	POTENTIAL BIOLOGIC AGENTS FOR TREATING RHEUMATOID ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 445-491.	1.9	17

#	ARTICLE	IF	CITATIONS
181	A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs. <i>Pharmacoeconomics</i> , 2001, 19, 715-728.	3.3	37
182	New Therapeutic Approaches to the Management of Rheumatoid Arthritis. <i>BioDrugs</i> , 2001, 15, 379-393.	4.6	17
183	Efficacy and Safety of Intraarticular Sodium Hyaluronate in Knee Osteoarthritis. <i>Clinical Orthopaedics and Related Research</i> , 2001, 385, 130-143.	1.5	132
184	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 653-661.	6.7	96
185	Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonism: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. <i>Arthritis and Rheumatism</i> , 2001, 44, 1977-1983.	6.7	296
186	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1984-1992.	6.7	275
187	TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 75-84.	1.8	44
188	Recombinant Human Relaxin in the Treatment of Scleroderma. <i>Annals of Internal Medicine</i> , 2000, 132, 871.	3.9	220
189	Practice Pattern Variation Among Internal Medicine Specialists in the Prevention of Glucocorticoid-Induced Osteoporosis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 117-122.	0.9	17
190	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 2445-2454.	6.7	252
191	Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. <i>Clinical Therapeutics</i> , 2000, 22, 128-139.	2.5	97
192	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1586-1593.	27.0	1,776
193	Title is missing!. <i>Arthritis Research</i> , 2000, 1, S47.	2.0	0
194	The treatment of rheumatoid arthritis: A review of recent clinical trials. <i>Current Rheumatology Reports</i> , 1999, 1, 135-138.	4.7	2
195	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999, 42, 357-365.	6.7	78
196	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
197	Specific Cyclooxygenase 2 Inhibitors: A New Choice of Nonsteroidal Anti-Inflammatory Drug Therapy. <i>Arthritis and Rheumatism</i> , 1999, 12, 351-362.	6.7	30
198	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96

#	ARTICLE	IF	CITATIONS
199	Clinical and pharmacological experience with etanercept. Expert Opinion on Investigational Drugs, 1999, 8, 1443-1451.	4.1	11
200	Etanercept Therapy in Rheumatoid Arthritis. Annals of Internal Medicine, 1999, 130, 478.	3.9	1,176
201	Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis. BioDrugs, 1999, 11, 201-210.	4.6	6
202	THE USE OF ANALGESICS IN THE MANAGEMENT OF PAIN IN RHEUMATIC DISEASES. Rheumatic Disease Clinics of North America, 1999, 25, 153-191.	1.9	12
203	Inter-observer reliability of the arthroscopic quantification of chondropathy of the knee. Osteoarthritis and Cartilage, 1998, 6, 160-166.	1.3	62
204	T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides. Arthritis and Rheumatism, 1998, 41, 1919-1929.	6.7	73
205	SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR (p75) FUSION PROTEIN (ENBREL) AS A THERAPY FOR RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America, 1998, 24, 579-591.	1.9	63
206	T-CELL RECEPTOR PEPTIDE VACCINATION IN THE TREATMENT OF RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America, 1998, 24, 641-650.	1.9	11
207	PERIOPERATIVE USE OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDERGOING ORTHOPEDIC SURGERY. Rheumatic Disease Clinics of North America, 1997, 23, 981-993.	1.9	36
208	Vaccination Against Rheumatoid Arthritis. BioDrugs, 1997, 8, 87-95.	4.6	2
209	Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)â€‘Fc Fusion Protein. New England Journal of Medicine, 1997, 337, 141-147.	27.0	1,586
210	Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis and Rheumatism, 1997, 40, 397-409.	6.7	143
211	Health status response of rheumatoid arthritis to treatment with DAB486IL-2. Arthritis and Rheumatism, 1996, 9, 112-119.	6.7	7
212	The Use of Methotrexate Perioperatively in Patients with Rheumatoid Arthritis Undergoing Major Joint Replacement Surgery. Journal of Clinical Rheumatology, 1996, 2, 6-8.	0.9	10
213	Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis and Rheumatism, 1996, 39, 257-265.	6.7	101
214	Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Arthritis and Rheumatism, 1996, 39, 1172-1177.	6.7	77
215	ASSESSMENT OF NEEDLE ARTHROSCOPY. Journal of Clinical Rheumatology, 1995, 1, 255.	0.9	0
216	Synovial Biopsy of the Knee Joint under Direct Visualization by Needle Arthroscopy. Journal of Clinical Rheumatology, 1995, 1, 103-109.	0.9	8

#	ARTICLE	IF	CITATIONS
217	Improved methotrexate patient information. Arthritis and Rheumatism, 1995, 38, 874-875.	6.7	1
218	Interleukin-2 diphtheria fusion protein (dab486il-2) in refractory rheumatoid arthritis a double-blind, placebo-controlled trial with open-label extension. Arthritis and Rheumatism, 1995, 38, 1177-1186.	6.7	62
219	Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-cd4 antibody, cm-t412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis and Rheumatism, 1995, 38, 1581-1588.	6.7	107
220	Treatment of refractory rheumatoid arthritis with a chimeric ANTI-CD4 monoclonal antibody. Arthritis and Rheumatism, 1994, 37, 834-838.	6.7	118
221	Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 307-318.	6.7	134
222	New Approaches to the Therapy of Autoimmune Diseases: Rheumatoid Arthritis As a Paradigm. American Journal of the Medical Sciences, 1993, 305, 40-51.	1.1	12
223	Effects of Nonsteroidal Antiinflammatory Drugs on Bone Loss in Chronic Inflammatory Disease. Annals of the New York Academy of Sciences, 1993, 696, 292-302.	3.8	19
224	Transforming growth factor $\beta^2$ within fibrotic scleroderma lungs. American Journal of Medicine, 1992, 93, 628-636.	1.5	23
225	Growth factors, extracellular matrix, and oncogenes in scleroderma. Arthritis and Rheumatism, 1992, 35, 304-310.	6.7	20
226	Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1991, 60, 412-418.	2.0	40
227	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. American Journal of Medicine, 1991, 90, 295-298.	1.5	59
228	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. American Journal of Medicine, 1991, 90, 295-298.	1.5	74
229	Rheumatoid arthritis patients and clinical drug trials A case-control study. Arthritis and Rheumatism, 1991, 4, 22-26.	6.7	7
230	Colchicine and gout. Arthritis and Rheumatism, 1991, 34, 782-786.	6.7	21
231	Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with methotrexate. Arthritis and Rheumatism, 1990, 3, 53-57.	6.7	0
232	Cutaneous polyarteritis nodosa. American Journal of Medicine, 1990, 88, 426-430.	1.5	69
233	Inflammatory central nervous system involvement in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 1989, 18, 258-266.	3.4	122
234	Spinal stenosis: A comprehensive review of the literature. Seminars in Arthritis and Rheumatism, 1989, 19, 127-149.	3.4	41

#	ARTICLE	IF	CITATIONS
235	Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Seminars in Arthritis and Rheumatism, 1989, 19, 31-44.	3.4	63
236	Immunohistologic demonstration of type ii collagen in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. Arthritis and Rheumatism, 1989, 32, 1458-1464.	6.7	23
237	Comment on the article by Furst et al. Arthritis and Rheumatism, 1989, 32, 1631-1632.	6.7	1
238	Intraarticular corticosteroid injections: Should we rest the joints?. Arthritis and Rheumatism, 1989, 2, 70-74.	6.7	34
239	Viral arthritis in humans. Current Opinion in Rheumatology, 1989, 1, 185-193.	4.3	0
240	Acute febrile neutrophilic dermatosis (sweet syndrome): A review of the literature with emphasis on musculoskeletal manifestations. Seminars in Arthritis and Rheumatism, 1988, 17, 143-155.	3.4	53
241	Ludwig's Angina. Archives of Internal Medicine, 1988, 148, 461.	3.8	85